EUCTR2015-004116-38-SE
Active, not recruiting
Phase 1
A clincial study comparing the effectiveness of two drugs, named Rituximab and Dimethyl Fumarate (Tecfidera®), for the neurological disease Multiple Sclerosis.
Department of Clinical Sciences, Danderyd Hospital0 sites200 target enrollmentOctober 20, 2015
ConditionsPatients with multiple sclerosis (MS) or patients presenting with symptoms highly suspicious of MS while not completely fulfilling diagnostic criteria, 18 - 50 years of age and no more than 10 years of disease duration (from diagnosis). Patients treated with immunomodulatory drugs or treated with first-line injectable therapies (eg interferons or glatiramer acetate) may be included.Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Patients with multiple sclerosis (MS) or patients presenting with symptoms highly suspicious of MS while not completely fulfilling diagnostic criteria, 18 - 50 years of age and no more than 10 years of disease duration (from diagnosis). Patients treated with immunomodulatory drugs or treated with first-line injectable therapies (eg interferons or glatiramer acetate) may be included.
- Sponsor
- Department of Clinical Sciences, Danderyd Hospital
- Enrollment
- 200
- Status
- Active, not recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •A subject will be eligible for inclusion in this study if all of the following criteria apply:
- •Diagnosis of Relapsing Remitting MS according to the 2017 revised McDonald criteria OR one demyelinating episode in conjunction with at least one asymptomatic high intensity T2 lesion with size and location compatible with MS
- •Untreated OR treated with first line injectables (interferon or glatiramer acetate)
- •Between the age of 18 and 50 years (inclusive) of age
- •No more than 10 years of disease duration (since MS diagnosis)
- •During the previous year, clinical or radiological disease activity defined as at least one of the following:
- •o \= 1 relapse
- •o \= 2 T2 lesions
- •o \= 1 Gd\+ lesions
- •EDSS 0 – 5,5 (inclusive)
Exclusion Criteria
- •A subject will not be eligible for inclusion in this study if any of the following criteria ap\-plies:
- •Diagnosis of Progressive MS
- •Pregnant or lactating women
- •Patients having contraindication for or otherwise not compliant with MRI investigations
- •Simultaneous treatment with other immunosuppressive drugs
- •Documented allergy or intolerance to any of the IP:s
- •Severe psychiatric condition
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A clincial study comparing the effectiveness of two doses of the drug Rituximab during long-term treatment of the neurological disease Multiple Sclerosis.EUCTR2018-000721-31-SEDepartment of Clinical Sciences, Karolinska Institutet Danderyd Hospital200
Recruiting
Phase 2
The effect of two topical drugs fluorouracil 5% and niacin amide 1% in the treatment of patients with actinic keratosisActinic keratosis.Actinic keratosisL57.0IRCT20220519054920N1Esfahan University of Medical Sciences88
Recruiting
Phase 3
Comparison of the clinical effectiveness of the two different doses of Meropenem in pneumoniaIRCT20100107003014N19Sari University of Medical Sciences62
Completed
Not Applicable
De beoordeling van de effectiviteit van twee probiotica bij het in stand houden van de mondgezondheid: een praktijkonderzoek.NL-OMON25529Ir. W. Th. FokkemaACTA Dental Research B.V. (ADR)Gustav Mahlerlaan 30041081 LA Amsterdam, NLw.fokkema@acta.nl / +31 6 28 724 788117
Completed
Not Applicable
The clinical evaluation of the effectiveness of two oral probiotic strains on gingival health.mondgezondheidgum diseaseNL-OMON46824Academisch Centrum Tandheelkunde Amsterdam (ACTA)117